Data on mix-and-match COVID-19 vaccine shots will soon be available from the National Institutes of Health, Dr. Anthony Fauci said. The studies are examining the safety and efficacy of booster shots made by a different drugmaker than the first dose or doses received by the individual. (CNBC Weekly)

As part of its increased focus on rare diseases, AstraZeneca will acquire Caelum for up to $500 million. Caelum’s principal drug is CAEL-101, a monoclonal antibody that aims to treat light chain amyloidosis. (Endpoints News)

Los Angeles is considering new vaccine mandates that, if implemented, would be the strictest in the country. The proposal includes vaccine requirements for entrance into malls, hair salons and movie theaters. (Business Insider)

Mirum Pharmaceuticals’ oral drug maralixibat has become the first approved treatment for Alagille syndrome in the U.S. The disease is a rare genetic disorder that causes the accumulation of bile in the liver. (Reuters)

Wearable health monitors may be able to predict infections even before symptoms appear, according to a new study published in the Journal of the American Medical Association. Researchers were able to detect infection with 92% accuracy in people inoculated with the H1N1 virus and human rhinovirus. (STAT)